- Successful turnaround achieved in 2013
- EBITDA pre one-time items increases by 8.5% to € 72 million following the implementation of efficiency measures
- EBITDA pre margin moves toward industry average thanks to profitability improvements
- Solid base for development in future years established
| XLS |
|
Consumer Health | Key figures |
|
||
|
|
|
|
|
|
|
|
|
|
|
€ million |
2013 |
2012 |
Change in % |
|
Total revenues |
479.6 |
475.2 |
0.9 |
|
Sales |
476.9 |
472.6 |
0.9 |
|
Operating result (EBIT) |
62.2 |
7.6 |
– |
|
Margin (% of sales) |
13.0 |
1.6 |
|
|
EBITDA |
71.1 |
29.8 |
138.6 |
|
Margin (% of sales) |
14.9 |
6.3 |
|
|
EBITDA pre one-time items |
72.5 |
66.8 |
8.5 |
|
Margin (% of sales) |
15.2 |
14.1 |
|
|
Business free cash flow |
83.9 |
88.8 |
–5.5 |
Development of total revenues and sales as well as results of operations
In 2013, the Consumer Health division reported a slight 0.9% increase in sales to € 477 million (2012: € 473 million). Strong organic growth of 5.6% was countered by a negative foreign exchange impact of –4.7%. Europe and Emerging Markets, the two largest regions in terms of sales, were the main drivers of the strong organic increases and the division’s overall positive development. Four of the eight strategic brands (Cebion®, Sangobion®, Kytta® and Femibion®) delivered double-digit organic growth rates and gained market share in the division’s key regions while the Bion®, Nasivin® and Sedalmerck® brands all posted growth rates in the mid-to-high single digits. The negative foreign exchange impact was broad-based, but particularly strong with respect to Latin American currencies, the British pound, the Indonesian rupiah, and the South African rand.
The development of sales in the individual quarters in comparison with 2012 as well as the respective organic growth rates are presented in the following table:
Consumer Health | Sales and organic growth by quarter 1
